TGFB1 and hepatocellular carcinoma: The data indicate that many HCC models respond to LXRα agonist and TGFβ stimulation; in certain HCCs, TGFβ partially antagonizes the stimulatory effect of T0901317 on FASN expression and LXRα stabilization.